Penumbra – Consensus Indicates Potential 76.8% Upside

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

Penumbra with ticker code (PEN) now have 6 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The target price ranges between 272 and 220 calculating the average target price we see 248.5. Now with the previous closing price of 140.52 this indicates there is a potential upside of 76.8%. The day 50 moving average is 170.45 and the 200 day moving average is 229.82. The company has a market capitalisation of $5,039m. You can visit the company’s website by visiting: https://www.penumbrainc.com

The potential market cap would be $8,911m based on the market concensus.

Penumbra designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand, as well as immersive computer-based technologies and immersive therapeutics to promote health, motor function, and cognition under the Real Immersive System brand; and a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and Packing Coil LP brands. The company sells its products through direct sales organizations and distributors. Penumbra was incorporated in 2004 and is headquartered in Alameda, California.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
Pennant International (LON:PEN) announces significant contracts, including a £4.9M RAF upgrade and new software and service deals in North America.
Pennant International Group plc (LON:PEN) offers a compelling investment opportunity in the defence sector, as discussed by Gervais Williams from Miton UK Microcap Trust plc (LON:MINI).
Pennant International Group plc's CEO Phil Walker discusses H1 trading update highlights, order intake progress, and the strategic launch of the Auxilium software suite.

Search

Search